Recent 8-K filings for CPIX

• May 5, 2026, 7:59 PM ET M&A materiality 0.90 positive item 2.02item 9.01 ◈ Earnings Releases

  Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M

  Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.

• April 24, 2026, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Cumberland shareholders elect two Class I directors, ratify auditor, approve say-on-pay

  Kenneth J. Krogulski elected with 99.52% votes in favor; Caroline R. Young with 98.66%.

• April 23, 2026, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 8.01item 9.01 ◈ Material Agreements

  Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline

  Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.

• March 3, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M

  Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.

• February 4, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01

  Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease

  FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.

• November 24, 2025, 6:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027

  Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).

• November 4, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M

  Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).

• October 21, 2025, 7:59 PM ET M&A materiality 0.60 positive item 8.01

  Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy

  Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.

• August 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%

  Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).

• May 6, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK

  Net revenue $11.7M vs $8.5M prior year, 38% increase.

• April 28, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Cumberland shareholders re-elect three directors, ratify auditor with >98% votes

  Directors Bernard, Galante, and Kazimi re-elected with 98.6%, 99.2%, and 99.6% votes in favor.

• March 19, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial

  High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.

• March 4, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M

  Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.

• February 19, 2025, 6:59 PM ET regulatory materiality 0.70 positive item 8.01

  Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone

  Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.

• February 14, 2025, 6:59 PM ET other material materiality 0.45 neutral item 8.01item 9.01

  Cumberland Pharmaceuticals increases ATM offering size to $10M

  Maximum aggregate offering price under Sales Agreement with H.C. Wainwright raised to $10,000,000.

• February 4, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01

  Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease

  High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.

• December 9, 2024, 6:59 PM ET regulatory materiality 0.65 positive item 8.01

  FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC

  FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.

• November 12, 2024, 6:59 PM ET regulatory materiality 0.55 positive item 8.01

  Cumberland Pharma receives FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban in DMD

  FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy.

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced

  Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).

• November 6, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01

  Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac

  Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.

• November 4, 2024, 6:59 PM ET regulatory materiality 0.80 negative item 8.01

  CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025

  CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.

• August 6, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive

  Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.

• May 7, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M

  Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.

• April 29, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  Cumberland Pharmaceuticals shareholders re-elect directors, ratify auditor at annual meeting

  Martin S. Brown, Jr. re-elected as Class II director with 96.0% of votes in favor (8,544,756 for, 352,239 withheld).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

15 positive 2 negative 7 neutral

source · CPIX on sec.gov